Sanofi terminates deal to exclusively license Maze Therapeutics Pompe disease drug
Advertisement
Washington: Sanofi has said it was terminating a deal to exclusively license a drug that Maze Therapeutics is developing to treat Pompe disease because of objections from the U.S. government.
The U.S. Federal Trade Commission said that it had decided to fight the proposed exclusive license because the arrangement would create a monopoly for medicines to treat Pompe disease.
Sanofi said that the "delay associated with a long litigation" had led it to terminate the planned deal.
The FTC valued the deal, which was announced in May 2023, at $755 million.
Pompe disease is a rare genetic condition where a person lacks a digestive enzyme. The disease causes muscle weakness and wasting and can be fatal if not treated.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.